Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies.
Abutaleb
Nasrulla
N
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D000418:Albumins / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D006530:Hepatorenal Syndrome / Q000188:drug therapy*; D006801:Humans; D009638:Norepinephrine / Q000009:adverse effects* / Q000627:therapeutic use; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000139:chemically induced*; D012307:Risk Factors
D000316:Adrenergic alpha-Agonists; D000418:Albumins; D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide; D009638:Norepinephrine